INTRODUCTION: The objectives of this survey were to assess the seroprevalence of antibodies to poliovirus types 1 and 3 and the impact of bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) use in immunization campaigns in northern India. METHODS: In August 2010, a 2-stage stratified cluster sampling method identified infants aged 6-7 months in high-risk blocks for wild poliovirus infection. Vaccination history, weight and length, and serum were collected to test for neutralizing antibodies to poliovirus types 1, 2, and 3. RESULTS: Seroprevalences of antibodies to poliovirus types 1, 2, and 3 were 98% (95% confidence interval [CI], 97%-99%), 66% (95% CI, 62%-69%), and 77% (95% CI, 75%-79%), respectively, among 664 infants from Bihar and 616 infants from Uttar Pradesh. Infants had received a median of 3 bOPV doses and 2 monovalent type 1 OPV (mOPV1) doses through campaigns and 3 trivalent OPV (tOPV) doses through routine immunization. Among subjects with 0 tOPV doses, the seroprevalences of antibodies to type 3 were 50%, 77%, and 82% after 2, 3, and 4 bOPV doses, respectively. In multivariable analysis, malnutrition was associated with a lower seroprevalence of type 3 antibodies. CONCLUSIONS: This study confirmed that replacing mOPV1 with bOPV in campaigns was successful in maintaining very high population immunity to type 1 poliovirus and substantially decreasing the immunity gap to type 3 poliovirus. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
INTRODUCTION: The objectives of this survey were to assess the seroprevalence of antibodies to poliovirus types 1 and 3 and the impact of bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) use in immunization campaigns in northern India. METHODS: In August 2010, a 2-stage stratified cluster sampling method identified infants aged 6-7 months in high-risk blocks for wild poliovirus infection. Vaccination history, weight and length, and serum were collected to test for neutralizing antibodies to poliovirus types 1, 2, and 3. RESULTS: Seroprevalences of antibodies to poliovirus types 1, 2, and 3 were 98% (95% confidence interval [CI], 97%-99%), 66% (95% CI, 62%-69%), and 77% (95% CI, 75%-79%), respectively, among 664 infants from Bihar and 616 infants from Uttar Pradesh. Infants had received a median of 3 bOPV doses and 2 monovalent type 1 OPV (mOPV1) doses through campaigns and 3 trivalent OPV (tOPV) doses through routine immunization. Among subjects with 0 tOPV doses, the seroprevalences of antibodies to type 3 were 50%, 77%, and 82% after 2, 3, and 4 bOPV doses, respectively. In multivariable analysis, malnutrition was associated with a lower seroprevalence of type 3 antibodies. CONCLUSIONS: This study confirmed that replacing mOPV1 with bOPV in campaigns was successful in maintaining very high population immunity to type 1 poliovirus and substantially decreasing the immunity gap to type 3 poliovirus. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Imtiaz Hussain; Ondrej Mach; Atif Habib; Zaid Bhatti; Zamir Suhag; M Steven Oberste; William C Weldon; Roland W Sutter; Sajid B Soofi; Zulfiqar A Bhutta Journal: Pediatr Infect Dis J Date: 2017-09 Impact factor: 3.806
Authors: Oumar Guindo; Ondrej Mach; Seydou Doumbia; Daniel K Ekra; Abdoul H Beavogui; William C Weldon; M Steven Oberste; Roland W Sutter Journal: Vaccine Date: 2018-01-19 Impact factor: 4.169
Authors: Daniel Olson; Molly M Lamb; Maria Renee Lopez; M Alejandra Paniagua-Avila; Alma Zacarias; Gabriela Samayoa-Reyes; Celia Cordon-Rosales; Edwin J Asturias Journal: Open Forum Infect Dis Date: 2017-03-17 Impact factor: 3.835
Authors: Natalie A Molodecky; Isobel M Blake; Kathleen M O'Reilly; Mufti Zubair Wadood; Rana M Safdar; Amy Wesolowski; Caroline O Buckee; Ananda S Bandyopadhyay; Hiromasa Okayasu; Nicholas C Grassly Journal: PLoS Med Date: 2017-06-12 Impact factor: 11.069
Authors: Richter Razafindratsimandresy; Ondrej Mach; Jean-Michel Heraud; Barivola Bernardson; William C Weldon; M Steven Oberste; Roland W Sutter Journal: Heliyon Date: 2018-03-07
Authors: Kirsten E Wiens; Barbara Jauregui; Benjamin F Arnold; Kathryn Banke; Djibril Wade; Kyla Hayford; Adriana Costero-Saint Denis; Robert H Hall; Henrik Salje; Isabel Rodriguez-Barraquer; Andrew S Azman; Guy Vernet; Daniel T Leung Journal: PLoS Negl Trop Dis Date: 2022-10-06
Authors: Sani Ousmane; Dan Dano Ibrahim; Ajay Goel; William S Hendley; Bernardo A Mainou; Tess Palmer; Aissata Diaha; Sharon A Greene; Ondrej Mach Journal: Open Forum Infect Dis Date: 2021-05-06 Impact factor: 3.835